Kolodny, Edwin H.
Edwin Hillel Kolodny
VIAF ID: 64301521 (Personal)
Permalink: http://viaf.org/viaf/64301521
Preferred Forms
- 100 0 _ ‡a Edwin Hillel Kolodny
- 200 _ | ‡a Kolodny ‡b Edwin H.
- 100 1 _ ‡a Kolodny, Edwin H.
- 100 1 _ ‡a Kolodny, Edwin H.
- 100 1 0 ‡a Kolodny, Edwin H.
-
- 100 1 _ ‡a Kolodny, Edwin H. (sparse)
-
-
-
4xx's: Alternate Name Forms (1)
Works
Title | Sources |
---|---|
Acute confusional migraine may be a presenting feature of CADASIL. | |
Anderson-Fabry disease: extrarenal, neurologic manifestations | |
Antisulfatide IgG antibodies recognize HIV proteins | |
Bioimaging in neurodegeneration | |
Bone marrow-derived mesenchymal stem cells remain host-derived despite successful hematopoietic engraftment after allogeneic transplantation in patients with lysosomal and peroxisomal storage diseases | |
Cerebrovascular involvement in Fabry disease: current status of knowledge | |
CNS pathology and vascular/circulatory abnormalities in Fabry disease | |
Correction of the galactocerebrosidase deficiency in globoid cell leukodystrophy-cultured cells by SL3-3 retroviral-mediated gene transfer | |
Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations | |
Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). | |
Enzyme replacement therapy improves cardiovascular responses to orthostatic challenge in Fabry patients | |
Fabry disease - underestimated in the differential diagnosis of multiple sclerosis? | |
Familial spastic paraparesis. Is it a mitochondrial disorder? | |
Family History in Young Patients With Stroke | |
Frequency of MELAS main mutation in a phenotype-targeted young ischemic stroke patient population | |
Gaucher disease: Basic and translational science needs for more complete therapy and management | |
Globoid cell leukodystrophy (Krabbe disease): normal umbilical cord blood galactocerebrosidase activity and polymorphic mutations | |
GM1-gangliosidosis in American black bears: clinical, pathological, biochemical and molecular genetic characterization | |
GM2-ganglioside metabolism in hexosaminidase A deficiency states: determination in situ using labeled GM2 added to fibroblast cultures | |
Hippocampal atrophy as a surrogate of neuronal involvement in Fabry disease. | |
A Human Kidney cDNA Which Induces a Cell Surface Protein Epitope Recognized by a Monoclonal Antibody against Galactosylceramide | |
In vivo and in vitro glioma cell killing induced by an adenovirus expressing both cytosine deaminase and thymidine kinase and its association with interferon-alpha. | |
Isolation and characterization of the normal canine beta-galactosidase gene and its mutation in a dog model of GM1-gangliosidosis | |
Juvenile-onset motor neuron disease caused by novel mutations in β-hexosaminidase | |
Late-onset GM2 gangliosidosis: Ashkenazi Jewish family with an exon 5 mutation (Tyr180-->His) in the Hex A alpha-chain gene | |
Late-onset Tay-Sachs disease: the spectrum of peripheral neuropathy in 30 affected patients | |
Lessons from everyday stroke care for clinical research and vice versa: comparison of a comprehensive and a research population of young stroke patients | |
Leukocyte beta-glucosidase in homozygotes and heterozygotes for Gaucher disease | |
Management of neuronopathic Gaucher disease: revised recommendations | |
Metabolic activities in human skin fibroblasts preloaded with labeled GM2-ganglioside. | |
Metronomic breathing shows altered parasympathetic baroreflex function in untreated Fabry patients and baroreflex improvement after enzyme replacement therapy | |
Miglustat in late-onset Tay-Sachs disease: a 12-month, randomized, controlled clinical study with 24 months of extended treatment | |
Mitochondrial encephalomyopathies presenting with features of autonomic and visceral dysfunction | |
Molecular heterogeneity of late-onset forms of globoid-cell leukodystrophy | |
MR imaging and proton spectroscopy of neuronal injury in late-onset GM2 gangliosidosis | |
A neurological symptom survey of patients with type I Gaucher disease | |
Neurology of hereditary metabolic diseases of children, c1996: | |
Neuronopathic Gaucher disease: demographic and clinical features of 131 patients enrolled in the International Collaborative Gaucher Group Neurological Outcomes Subregistry | |
Patent Foramen Ovale and Cryptogenic Strokes in the Stroke in Young Fabry Patients Study | |
Pathology of GM2 gangliosidosis in Jacob sheep | |
Phenotypic manifestations of Gaucher disease: clinical features in 48 biochemically verified type 1 patients and comment on type 2 patients | |
Phenotypic Spectrum of Hematological and Visceral Disease in Type 3 Gaucher Disease and Response to Imiglucerase Therapy: Preliminary Analysis from the ICGG Gaucher Registry | |
Rapid detection of three large novel deletions of the aspartoacylase gene in non-Jewish patients with Canavan disease | |
Re: Neurocognitive testing in late-onset Tay-Sachs disease: a pilot study | |
Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease. | |
Roscoe Owen Brady, MD: Remembrances of co-investigators and colleagues | |
Substitution of Alanine543 with a Threonine Residue at the Carboxy Terminal End of the β-Chain Is Associated with Thermolabile Hexosaminidase B in a Jewish Family of Oriental Ancestry | |
Tay-Sachs disease in Jacob sheep | |
Therapeutic effects of astrocytes expressing both tyrosine hydroxylase and brain-derived neurotrophic factor on a rat model of Parkinson's disease | |
Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry. | |
Two abnormalities of hexosaminidase A in clinically normal individuals. | |
Very long chain acyl-CoA dehydrogenase deficiency in a pair of mildly affected monozygotic twin sister in their late fifties. |